TABLE 4.

Cost-Effectiveness Ratios From Base-Case and Sensitivity Analyses of Pneumococcal Conjugate Vaccination in $/Life-Year or $/QALY

Base-Case AssumptionsDirect Medical Costs Half of BaselineDirect Medical Costs Twice BaselineDisease Incidence Half of BaselineDisease Incidence Twice BaselineDirect Medical Costs and Disease Incidence Rates at Half of BaselineDirect Medical Costs and Disease Incidence Rates at Twice Baseline
Original analysis* ($/Life-Year)110 000407 000Cost saving163 000Cost saving462 000Cost saving
Median TTO values ($/QALY)
 Parent<5000<5000<500010 000<500011 000Cost saving
 Community<5000<5000<50006000<50007000Cost saving
25th percentile TTO values ($/QALY)
 Parent125 000154 00067 000320 00028 000349 000Cost saving
 Community29 00036 00016 00074 000600081 000Cost saving
75th percentile TTO values ($/QALY)
 Parent<5000<5000<5000<5000<5000<5000Cost saving
 Community<5000<5000<5000<5000<5000<5000Cost saving
  • TTO indicates time trade-off.

  • * The original analysis does not include morbidity effects but does include dollar costs for work loss, which results in cost savings in some scenarios.